ARTBIO Raises $132M Series B to Advance Alpha Radiotherapy Pipeline and Manufacturing with Pb212

ARTBIO closed a $132 million Series B financing round on July 29, 2025, led by Sofinnova Investments and B Capital, with participation from F-Prime, Omega Funds, Third Rock Ventures, Qatar Investment Authority, and Alexandria Venture Investments1234.

The funding will be used to advance the clinical development of ARTBIO's lead asset AB001, which targets metastatic castration-resistant prostate cancer, further pipeline programs, and expand the company’s distributed manufacturing and supply chain infrastructure1234.

ARTBIO develops alpha radioligand therapies (ARTs), which are precision cancer treatments utilizing alpha-emitting isotopes — specifically, their proprietary AlphaDirect technology enables flexible and reliable production and supply of clinical-grade lead-212 (Pb212) for these therapies234.

The funding supports the company's plans to reinforce their distributed manufacturing network, aiming for global clinical trials and future commercial supply, addressing supply challenges common in radiopharmaceuticals124.

ARTBIO's AlphaDirect platform and selection of Pb212 as the alpha-precursor isotope are described as key differentiators intended to maximize therapeutic efficacy and safety in cancer care34.

Sources:

1. https://artbio.com/artbio-raises-132m-series-b-to-advance-alpha-radioligand-therapies-and-expand-infrastructure/

2. https://www.pharmaceuticalprocessingworld.com/artbio-raises-132m-to-expand-supply-chain-manufacturing-capabilities/

3. https://vcnewsdaily.com/artbio/venture-capital-funding/ljqtffyzfg

4. https://www.axios.com/pro/biotech-deals/2025/07/29/artbio-132m-cancer-therapies-radiopharma-series-b